// App-Quantinova.ai

SAT0104 : MAINTENANCE OF SDAI REMISSION AND PATIENT-REPORTED OUTCOMES (PROS) FOLLOWING DOSE DE-ESCALATION OF ABATACEPT IN MTX-NAÏVE, ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+ PATIENTS WITH EARLY RA: RESULTS FROM AVERT-2, A RANDOMISED PHASE IIIB STUDY

Researchers

Presenter

  • P. Emery

Principal Investigators

  • Y. Tanaka

  • V. Bykerk

  • T. Huizinga

  • G. Citera

  • C. Bingham

  • S. Banerjee

  • S. Connolly

  • J. Zhuo

  • R. Wong

  • K. H. G. Huang

  • K. Lozenski

  • Y. Elbez

  • R. Fleischmann

Medical Centers

  • LIRMM, University of Leeds, NIHR BRC LTHT, Leeds, United Kingdom

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • Leiden University Medical Centre, Leiden, Netherlands

  • Instituto de Rehabilitacion Psicofisica, Buenos Aires, Buenos Aires, Argentina

  • The Johns Hopkins University, Baltimore, United States of America

  • Bristol-Myers Squibb Company, Lawrencville, NJ, United States of America

  • Excelya, Boulogne-Billancourt, France,

Locations

  • United Kingdom

  • Japan

  • United States

  • Netherlands

  • Argentina

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02504268

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved